This joint resolution (SJRES 100) seeks to block an Environmental Protection Agency (EPA) rule that sets new air pollution standards for specific chemical manufacturing industries. It directly targets the Synthetic Organic Chemical Manufacturing Industry and Group I & II Polymers and Resins Industry by requesting Congress disapprove the EPA's rule published in the Federal Register (89 Fed. Reg. 42932, May 16, 2024). The resolution uses a statutory process (under chapter 8 of title 5, U.S. Code) to formally reject the rule, which would prevent it from taking effect. If passed, the EPA rule establishing emission limits for hazardous air pollutants and new source performance standards would have no legal force. This is a procedural disapproval effort, not a new environmental policy.
This bill (SJRES 99) is a congressional resolution seeking to block a specific environmental regulation. It targets the Council on Environmental Quality's "National Environmental Policy Act Implementing Regulations Revisions Phase 2" rule, which was published in the Federal Register on May 1, 2024. If passed, the resolution would formally disapprove this rule, preventing it from taking effect and halting its implementation by federal agencies. The rule would have modified how agencies conduct environmental reviews under the National Environmental Policy Act (NEPA), but the resolution directly stops that change without altering NEPA itself.
This is a ceremonial Senate resolution (SRES 739) introduced by Senators Rubio, Tuberville, and others on June 18, 2024. It commemorates the second anniversary of the Supreme Court's June 24, 2022, *Dobbs v. Jackson Women's Health Organization* decision, which overturned *Roe v. Wade*. The resolution expresses support for the Court's ruling that the Constitution does not guarantee a right to abortion, and it includes statements about protecting "unborn life" and supporting families. As a symbolic measure, it does not create new laws or policies.
HRES 1305 is a procedural resolution that formally rescinds subpoenas issued by the January 6th Select Committee to four individuals (Stephen Bannon, Mark Meadows, Daniel Scavino Jr., and Peter Navarro) and withdraws the committee’s recommendations finding them in contempt of Congress. The bill specifically cancels subpoenas from September 2021, October 2021, and February 2022, along with related contempt resolutions adopted in 2021-2022. It does not alter legal proceedings but withdraws the committee’s authority to enforce these actions. The resolution is supported by House members who argue the committee was partisan and illegitimate, though the bill itself only addresses the committee’s procedural actions.
The Creating Hope Reauthorization Act of 2024 extends the expiration date of the priority review voucher program for rare pediatric disease treatments from September 30, 2024, to September 30, 2030. This program, established under the Federal Food, Drug, and Cosmetic Act, allows the FDA to issue priority review vouchers to pharmaceutical companies that develop treatments for rare pediatric diseases. These vouchers enable companies to expedite FDA review of other drug applications, creating a financial incentive to invest in rare disease research. The extension ensures continued support for developing treatments for rare pediatric conditions through 2030.
This bill reauthorizes and extends existing Alzheimer's disease and dementia programs through fiscal year 2029. It specifically provides $33 million annually for states and public health departments to support Alzheimer's initiatives, including community-based care and research translation. Key provisions require translating clinical trial findings into community practices and strengthen coordination with the CDC. The bill directly affects state health agencies and public health departments receiving federal funding for dementia care programs. It does not create new programs but extends current funding mechanisms and adds a new requirement to apply research findings to community-level interventions.
This bill rescinds unspent funds from specific federal programs. It targets leftover money from pandemic relief (like the CARES Act and American Rescue Plan) and certain infrastructure initiatives (including education stabilization funds and transportation programs like the Congestion Mitigation Program). The rescission is limited to amounts already allocated for Israel, Ukraine, and Indo-Pacific security supplements under recent appropriations. Unspent funds must be returned to the Treasury, with no new spending created.
HRES 1303 is a resolution passed by the U.S. House of Representatives on June 14, 2024, that condemns the Biden administration's suspension of pending approvals for liquefied natural gas (LNG) exports to countries without free trade agreements with the U.S. The resolution argues this action is politically motivated, citing studies showing economic benefits of LNG exports and noting that previous administrations conducted similar environmental reviews without halting permits. It calls for lifting the suspension to restore confidence in the energy sector, prioritize U.S. workers and communities, and align with the administration's stated goals of economic growth. As a non-binding resolution, it does not change policy but formally expresses congressional disapproval of the administration's approach.
This joint resolution (SJRES 97) seeks to block a Department of Labor rule finalized in April 2024 that redefined overtime exemptions for certain white-collar workers. The rule would have changed how employers classify executive, administrative, professional, outside sales, and computer employees for overtime pay purposes. By invoking Chapter 8 of Title 5, U.S. Code, this resolution aims to nullify the rule, preventing it from taking effect. It directly affects employers and workers covered by the rule, but the resolution itself does not change existing labor standards - it only prevents the rule from being implemented.
The Mandatory E-Verify Act of 2024 would require all U.S. employers to use a permanent electronic verification system to confirm the employment eligibility of all new hires, with implementation deadlines based on company size (from 6 months to 18 months after enactment). The bill establishes specific procedures for handling verification results, including a 10-business-day process for resolving tentative non-confirmations, and imposes penalties for employers who fail to use the system. It also requires states to share driver's license information with the E-Verify system, with potential loss of federal funding for non-compliant states. The law aims to prevent unauthorized employment while including provisions for fraud prevention and worker protections.
This bill requires Medicare Advantage plans (private insurance plans that cover Medicare benefits) to implement electronic systems for prior authorization requests by 2027, replacing outdated methods like fax. Starting in 2026, these plans must publicly report detailed data on prior authorization decisions - including approval/denial rates, appeal outcomes, and processing times - to the government. The government will publish this data online so seniors and providers can see how plans handle requests. These changes aim to reduce delays in care for seniors by making the process more transparent and timely.
S 4533 (RESTORE Act) aims to improve access to restorative reproductive medicine for women with conditions like endometriosis, fibroids, and polycystic ovary syndrome. It requires federal reports assessing standard care for infertility and reproductive health conditions, including access to fertility awareness methods and restorative treatments. The bill expands national health surveys to track reproductive health needs, prohibits discrimination against providers who don't use assisted reproductive technology, and directs funding toward training in restorative approaches like NaProTECHNOLOGY. It directly affects women experiencing infertility (15-16% of couples), healthcare providers, and insurance plans covering these services. The law focuses on diagnostic and treatment pathways rather than assisted reproduction, emphasizing evidence-based care for underlying conditions.
